Blueprint Medicines Free Cash Flow 2014-2024 | BPMC

Blueprint Medicines free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.

  • Blueprint Medicines annual free cash flow for 2023 was $-0.453B, a 11.4% decline from 2022.
  • Blueprint Medicines annual free cash flow for 2022 was $-0.511B, a 69.41% increase from 2021.
  • Blueprint Medicines annual free cash flow for 2021 was $-0.302B, a 178.6% decline from 2020.

Blueprint Medicines Free Cash Flow 2014-2024 | BPMC

  • Blueprint Medicines annual free cash flow for 2023 was $-0.453B, a 11.4% decline from 2022.
  • Blueprint Medicines annual free cash flow for 2022 was $-0.511B, a 69.41% increase from 2021.
  • Blueprint Medicines annual free cash flow for 2021 was $-0.302B, a 178.6% decline from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$160.6B
Vertex Pharmaceuticals (VRTX)$126.2B
Bristol Myers Squibb (BMY)$119.7B
Gilead Sciences (GILD)$117.5B
Regeneron Pharmaceuticals (REGN)$90.2B
CSL (CSLLY)$90B
GSK (GSK)$73.6B
Argenex SE (ARGX)$35.5B
Alnylam Pharmaceuticals (ALNY)$34.7B
BioNTech SE (BNTX)$25.5B
Biogen (BIIB)$24.5B
Illumina (ILMN)$23.4B
BeiGene (BGNE)$18.9B
Moderna (MRNA)$16.7B
Incyte (INCY)$15.5B
Genmab (GMAB)$14.9B
BioMarin Pharmaceutical (BMRN)$12.6B
Insmed (INSM)$12.5B
Vaxcyte (PCVX)$12.4B
Bio-Techne Corp (TECH)$11.8B
Sarepta Therapeutics (SRPT)$10.9B
Exelixis (EXEL)$10.2B
Revolution Medicines (RVMD)$10B
QIAGEN (QGEN)$9.9B
Intra-Cellular Therapies (ITCI)$9.4B
Bio-Rad Laboratories (BIO.B)$9.4B
Exact Sciences (EXAS)$9.3B
Roivant Sciences (ROIV)$8.6B
Repligen (RGEN)$8.3B
Ascendis Pharma (ASND)$7.7B